Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comprehensive characterization of the human neural stem cell line HNSC.100 as a versatile model for neurobiological research.

Biochemistry and biophysics reports·2026
Same author

Nucleotide-dependent switching and RIPb effector recognition of the barley susceptibility factor RACB.

Communications biology·2026
Same author

Screening assay to monitor mono-ADP-ribosylhydrolase activity of viral macrodomains in cells.

Communications biology·2026
Same author

The yeast phosphofructokinase β-subunit has RNA unwinding activity and modulates cell cycle progression.

Nucleic acids research·2026
Same author

MiMiCPy-FM: A User-Friendly Force Matching Tool for Extending the Time Scale of QM/MM MD MiMiC Simulations.

Journal of chemical information and modeling·2026
Same author

Binding pose depth modulates photoswitchable ligands' efficacy at the 5-HT<sub>2A</sub> receptor.

Communications chemistry·2026
Same journal

From Pixels to Patterns: A Multidimensional Framework to Decode Cytoskeletal Organization.

Computational and structural biotechnology journal·2026
Same journal

A Large Concept Model for Mechanistic Simulation of Disease Trajectories: A Hypothesis-Generating Exemplar for Pediatric Acute Lymphoblastic Leukemia.

Computational and structural biotechnology journal·2026
Same journal

Adversarial Sequence Mutations in AlphaFold and ESMFold Reveal Nonphysical Structural Invariance, Confidence Failures, and Concerns for Protein Design.

Computational and structural biotechnology journal·2026
Same journal

High-Throughput Prediction of Protein-Protein Interactions Uncovers Hidden Molecular Networks in Biosynthetic Gene Clusters.

Computational and structural biotechnology journal·2026
Same journal

A Region-Aware Structured Framework Improves Prediction of Gene Expression from DNA Methylation.

Computational and structural biotechnology journal·2026
Same journal

Ensemble Machine Learning Approaches Predict Survival in Lower-Grade Glioma Based on Glycosphingolipid Gene Expression and Metabolic Modeling.

Computational and structural biotechnology journal·2026
See all related articles

Related Experiment Video

Updated: Oct 5, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K

Small-molecule modulators of TRMT2A decrease PolyQ aggregation and PolyQ-induced cell death.

Michael A Margreiter1,2, Monika Witzenberger3, Yasmine Wasser4

  • 1Institute of Neuroscience and Medicine (INM-9), Forschungszentrum Juelich GmbH, Germany.

Computational and Structural Biotechnology Journal
|January 24, 2022
PubMed
Summary
This summary is machine-generated.

Researchers identified TRMT2A inhibitors to treat polyglutamine (polyQ) diseases. These compounds reduced polyQ aggregation and cell death, indicating TRMT2A is a viable drug target for these neurodegenerative conditions.

Keywords:
AggregationComputer-aided drug discoveryPolyQRNA recognition motifTRMT2A

More Related Videos

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.6K
Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
10:50

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons

Published on: April 24, 2021

1.1K

Related Experiment Videos

Last Updated: Oct 5, 2025

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species
07:08

Fractionation for Resolution of Soluble and Insoluble Huntingtin Species

Published on: February 27, 2018

9.7K
Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity
08:16

Caenorhabditis elegans as a Model System for Discovering Bioactive Compounds Against Polyglutamine-Mediated Neurotoxicity

Published on: September 21, 2021

3.6K
Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons
10:50

Molecular Modulation by Lentivirus-Delivered Specific shRNAs in Endoplasmic Reticulum Stressed Neurons

Published on: April 24, 2021

1.1K

Area of Science:

  • Biochemistry
  • Genetics
  • Pharmacology

Background:

  • Polyglutamine (polyQ) diseases stem from expanded CAG trinucleotide repeats.
  • TRMT2A was previously identified as a key modifier of polyQ toxicity in Drosophila.
  • Targeting TRMT2A offers a potential therapeutic strategy for polyQ diseases.

Purpose of the Study:

  • To identify and validate pharmacological TRMT2A inhibitors for human polyQ diseases.
  • To explore TRMT2A as a druggable target for polyQ disease treatment.

Main Methods:

  • Computer-aided drug discovery for TRMT2A inhibitors.
  • Crystal structure determination of the TRMT2A RNA recognition motif (RRM).
  • Biacore experiments to characterize RRM interactions.
  • In vitro validation in HEK293T cells and patient-derived fibroblasts.

Main Results:

  • Identification of novel human TRMT2A inhibitors.
  • Structural insights into the TRMT2A RRM domain.
  • Demonstrated reduction of polyQ aggregation by identified compounds.
  • Validated efficacy in reducing polyQ-induced cell death in human cell models.

Conclusions:

  • TRMT2A is a viable drug target for polyQ diseases.
  • Pharmacological inhibition of TRMT2A is a promising therapeutic avenue.
  • This study represents a significant first step towards developing TRMT2A-based therapies.